Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer

Acta Oncologica

Volumn 54, Issue 7, 2015, Pages 971-978

  Chadha, Awalpreet S ^a   Kocak Uzel, Esengul ^a   Das, Prajnan ^a   Minsky, Bruce D ^a   Delclos, Marc E ^a   Mahmood, Usama ^a   Guha, Sushovan ^b   Ahmad, Mediha ^a   Varadhachary, Gauri R ^a   Javle, Milind ^a   Katz, Matthew H ^a   Fleming, Jason B ^a   Wolff, Robert A ^a   Crane, Christopher H ^a   Krishnan, Sunil ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CA 19-9 ANTIGEN; CAPECITABINE; CETUXIMAB; CISPLATIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; VORINOSTAT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PARANEOPLASTIC THROMBOCYTOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOSIS; WEIGHT REDUCTION; BLOOD; COMPLICATION; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PARANEOPLASTIC SYNDROMES; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PARANEOPLASTIC SYNDROMES; PLATELET COUNT; PROGNOSIS; RETROSPECTIVE STUDIES; THROMBOCYTOSIS;

EID: 84930902234     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2014.1000466     Document Type: Article

References (34)

1. Trousseau A. Lectures on clinical medicine, delivered at the Hotel-Dieu, Paris. 1865; 5: 281-332.
2. Stone R L, Nick AM, M cNeish I A, Balkwill F, Han H D, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. New Engl J Med 2012; 366: 610-8.
3. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002; 9: 287-91.
4. Symbas N P, Townsend M F, E l-Galley R, Keane TE, Graham SD, Petros JA. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. Br J Urol Int 2000; 86: 203-7.
5. Borsig L. The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther 2008; 8: 1247-55.
6. Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost 2004; 30: 95-108.
7. Caine GJ, Lip GY, Blann A D. P latelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: Further evidence for a role of platelets in tumour angiogenesis. Ann Med 2004; 36: 273-7.
8. Karpatkin S, Pearlstein E, Ambrogio C, Coller BS. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest 1988; 81: 1012-9.
9. Aminian A, Karimian F, Mirsharifi R, Alibakhshi A, Dashti H, Jahangiri Y, et al. Signifi cance of platelet count in esophageal carcinomas. Saudi J Gastroenterol 2011; 17: 134-7.
10. Schwarz R E, Keny H. Preoperative platelet count predicts survival after resection of periampullary adenocarcinoma. Hepatogastroenterology 2001; 48: 1493-8.
11. Willett C G, Czito B G, Bendell J C, Ryan D P. Locally advanced pancreatic cancer. J Clin Oncol 2005; 23: 4538-44.
12. Gutt R, Liauw SL, Weichselbaum RR. The role of radiotherapy in locally advanced pancreatic carcinoma. Nature Rev Gastroenterol Hepatol 2010; 7: 437-47.
13. Katz MH, Pisters PW, Evans DB, Sun C C, Lee JE, Fleming JB, et al. Borderline resectable pancreatic cancer: The importance of this emerging stage of disease. J Am Coll Surg 2008; 206: 833-46; discussion 46-8.
14. Heinemann V, Haas M, Boeck S. Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol 2013; 24: 2484-92.
15. Krishnan S, Rana V, Janjan NA, Abbruzzese JL, Gould MS, Das P, et al. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer 2006; 107: 2589-96.
16. Ikeda M, Okada S, Tokuuye K, Ueno H, Okusaka T. Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 2001; 91: 490-5.
17. Sezgin C, Karabulut B, Uslu R, Sanli UA, Goksel G, Yuzer Y, et al. Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors. Scand J Gastroenterol 2005; 40: 1486-92.
18. Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefi t from consolidative chemoradiation therapy. Cancer 2007; 110: 47-55.
19. Vainshtein JM, Schipper M, Zalupski MM, Lawrence TS, Abrams R, Francis IR, et al. Prognostic signifi cance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: Analysis of a prospective phase = dose escalation study. Int J Radiat Oncol Biol Phys 2013; 86: 96-101.
20. Tas F, Sen F, Odabas H, Kilic L, Keskin S, Yildiz I. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. Int J Clin Oncol 2013; 18: 839-46.
21. Sugrue T, Lowndes N F, Ceredig R. Hypoxia enhances the radioresistance of mouse mesenchymal stromal cells. Stem Cells 2014; 32: 2188-200.
22. Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 2008; 68: 605-14.
23. Schack J A, Macduffee R C. Increased radioresistance of red bone marrow after anoxia. Science 1949; 110: 259-60.
24. Wojtukiewicz MZ, Sierko E, Rak J. Contribution of the hemostatic system to angiogenesis in cancer. Semin Thromb Hemost 2004; 30: 5-20.
25. Folkman J, Browder T, Palmblad J. Angiogenesis research: Guidelines for translation to clinical application. Thromb Haemost 2001; 8: 23-33.
26. Ho-Tin-Noe B, Goerge T, Wagner DD. P latelets: Guardians of tumor vasculature. Cancer Res 2009; 69: 5623-6.
27. Wojtukiewicz MZ, Sierko E, Klement P, Rak J. The hemostatic system and angiogenesis in malignancy. Neoplasia (New York, NY). 2001; 3: 371-84.
28. Sawicki G, Salas E, Murat J, M iszta-Lane H, Radomski MW. Release of gelatinase Aduring platelet activation mediates aggregation. Nature 1997; 386: 616-9.
29. Belloc C, Lu H, Soria C, Fridman R, Legrand Y, Menashi S. The effect of platelets on invasiveness and protease production of human mammary tumor cells. Int J Cancer 1995; 60: 413-7.
30. Gao J, Aksoy B A, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profi les using the cBioPortal. Sci Signal 2013; 6: pl1.
31. Cerami E, Gao J, Dogrusoz U, Gross B E, Sumer S O, Aksoy BA, et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-4.
32. Graf G, Dehmel U, Drexler HG. Expression of thrombopoietin and thrombopoietin receptor MPL in human leukemialymphoma and solid tumor cell lines. Leukemia Res 1996; 20: 831-8.
33. Columbyova L, Loda M, Scadden D T. Thrombopoietin receptor expression in human cancer cell lines and primary tissues. Cancer Res 1995; 55: 3509-12.
34. Akl EA, van Doormaal FF, Barba M, Kamath G, Kim SY, Kuipers S, et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev 2007; (3): CD006652.